Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Атмосфера. Новости кардиологии
2023 / N 3

Подходы к преодолению терапевтического нигилизма при лечении артериальной гипертонии у лиц пожилого возраста
С.Р. Гиляревский, А.Ю. Щедрина, К.А. Ерусланова, Н.Г. Бенделиани, М.В. Голшмид, О.Н. Ткачева

References

1. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal 2018 Sep;39(33):3021­104.
2. Chiu N, Chiu L, Aggarwal R, Raber I, Bhatt DL, Mukamal KJ. Trends in blood pressure treatment intensification in older adults with hypertension in the United States, 2008 to 2018. Hypertension (Dallas, Tex.: 1979) 2023 Mar;80(3):553­62.
3. Flack JM, Cheema A. Therapeutic nihilism in older hypertensives: a resounding call to action. Hypertension (Dallas, Tex.: 1979) 2023 Mar;80(3):563­5.
4. Jaeger BC, Bress AP, Bundy JD, Cheung AK, Cushman WC, Drawz PE, Johnson KC, Lewis CE, Oparil S, Rocco MV, Rapp SR, Supiano MA, Whelton PK, Williamson JD, Wright JT Jr, Reboussin DM, Pajewski NM. Longer­term all­cause and cardiovascular mortality with intensive blood pressure control: a secondary analysis of a randomized clinical trial. JAMA Cardiology 2022 Nov;7(11):1138­46.
5. Fatani N, Dixon DL, Van Tassell BW, Fanikos J, Buckley LF. Systolic blood pressure time in target range and cardiovascular outcomes in patients with hypertension. Journal of the American College of Cardiology 2021 Mar;77(10):1290­9.
6. Lin Z, Xiao Z, Chen W, Xu W, Huang C, Xie J, Jin M, Wei X, He S, Xie Z, Liao W, Liao Y, Feng W, Chen Y, Bin J. Association of long­term time in target range for systolic blood pressure with cardiovascular risk in the elderly: a Chinese veteran cohort study. European Journal of Preventive Cardiology 2023 Aug;30(10):969­77.
7. Wang J, Jiang C, Li S, Wang Z, Wang Y, Lai Y, Wang Z, Lv W, Bai Y, Yang Z, Guo Q, Huang L, He L, Guo X, Li S, Liu N, Jiang C, Tang R, Long D, Du X, Sang C, Dong J, Ma C. Systolic blood pressure time in target range and incident atrial fibrillation in patients with hypertension: insights from the SPRINT trial. Hypertension (Dallas, Tex.: 1979) 2023 Nov;80(11):2306­14.
8. Li S, Jiang C, Wang Y, Lai Y, Zhao M, Li Q, Bai Y, Dai W, Guo Q, He L, Guo X, Wang W, Li S, Liu N, Jiang C, Tang R, Sang C, Long D, Du X, Dong J, Anderson CS, Ma C. Systolic blood pressure time in target range and cognitive outcomes: insights from the SPRINT MIND trial. Hypertension (Dallas, Tex.: 1979) 2023 Aug;80(8):1628­36.
9. Makani H, Bangalore S, Supariwala A, Romero J, Argulian E, Messerli FH. Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta­analysis. European Heart Journal 2014 Jul;35(26):1732­42.
10. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. The Lancet 2004 Jun;363(9426):2022­31.
11. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double­blind intervention trial. Journal of Hypertension 2003 May;21(5):875­86.
12. Kjeldsen SE, Stålhammar J, Hasvold P, Bodegard J, Olsson U, Russell D. Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. Journal of Human Hypertension 2010 Apr;24(4):263­73.
13. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH Jr, Messerli FH, Oparil S, Schork MA; Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin­receptor blocker. The New England Journal of Medicine 2006 Apr;354(16):1685­97.
14. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta­analysis on 11,000 participants from 42 trials. The American Journal of Medicine 2009 Mar;122(3):290­300.
15. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM­Overall programme. The Lancet 2003 Sep;362(9386):759­66.
16. Yusuf S, Ostergren JB, Gerstein HC, Pfeffer MA, Swedberg K, Granger CB, Olofsson B, Probstfield J, McMurray JV; Candesartan in Heart Failure­Assessment of Reduction in Mortality and Morbidity Program Investigators. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005 Jul;112(1):48­53.
17. Nasser M, Chedid P, Salami A, Khalifeh M, El Shamieh S, Joumaa WH. Dataset on significant role of candesartan on cognitive functions in rats having memory impairment induced by electromagnetic waves. Data in Brief 2018 Nov;21:2390­4.
18. Trofimiuk E, Wielgat P, Braszko JJ. Candesartan, angiotensin II type 1 receptor blocker is able to relieve age­related cognitive impairment. Pharmacological Reports 2018 Feb;70(1):87­92.
19. Hajjar I, Okafor M, McDaniel D, Obideen M, Dee E, Shokouhi M, Quyyumi AA, Levey A, Goldstein F. Effects of candesartan vs lisinopril on neurocognitive function in older adults with executive mild cognitive impairment: a randomized clinical trial. JAMA Network Open 2020 Aug;3(8):e2012252.
20. Trenkwalder P. The Study on COgnition and Prognosis in the Elderly (SCOPE) – recent analyses. Journal of Hypertension. Supplement 2006 Mar;24(1):S107­14.
21. Cernes R, Mashavi M, Zimlichman R. Differential clinical profile of candesartan compared to other angiotensin receptor blockers. Vascular Health and Risk Management 2011;7:749­59.
22. Van Liefde I, Vauquelin G. Sartan­AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism. Molecular and Cellular Endocrinology 2009;302:237­43.
23. Morsing P, Adler G, Brandt­Eliasson U, Karp L, Ohlson K, Renberg L, Sjöquist PO, Abrahamsson T. Mechanistic differences of various AT1­receptor blockers in isolated vessels of different origin. Hypertension (Dallas, Tex.: 1979) 1999 Jun;33(6):1406­13.
  

[ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]